IOLCP gets nod for facilities from European health regulator

NEW DELHI: Drug firm IOL Chemicals and Pharmaceuticals ( IOLCP) today said it has received the certificate of suitability (CEP) from European health regulator for its manufacturing facilities for the non-steroidal anti-inflammatory drug 'Ibuprofen'.

The CEP has been given by the European Directorate for the Quality of Medicines and Healthcare (EDQM), the company said in a filing to the Bombay Stock Exchange (BSE).

EQDM is the technical secretariat of the European Pharmacopoeia Commission.

CEPs are recognised by the signatory member states of the European Pharmacopoeia Commission. All medicines sold in the member states of the European Pharmacopoeia must comply with these quality standards.

Shares of IOLCP were trading at Rs 61.85 on the BSE in the afternoon trade, up 11.74 per cent from its previous close.